IMVT - Immunovant, Inc.
After hours:
Chart Events
Slow Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 21.07 |
| Open | 21.01 |
| Bid | 20.93 x 900 |
| Ask | 22.00 x 1300 |
| Day's Range | 20.84 - 21.36 |
| 52 Week Range | 3.14 - 24.18 |
| Volume | |
| Avg. Volume | 987,319 |
| Market Cap | 2.745B |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.70 |
| Earnings Date | Aug 03, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.50 |
Fair Value
Related Research
ZacksImmunovant (IMVT) Q4 Earnings Top Estimates, Pipeline in Focus
Immunovant (IMVT) reports narrower-than-expected results in fourth-quarter fiscal 2023. Pipeline development is on track. Stock surges 12% on Monday.
Simply Wall St.Estimating The Intrinsic Value Of Immunovant, Inc. (NASDAQ:IMVT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Immunovant fair value estimate is US$21.98 Immunovant's...
- GlobeNewswire
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectivelyPhase 1 clinical trial in healthy subjects initiated in New ZealandPhase 2 proof-of-concept clinical trial of batoclimab in Graves’ disease (GD) initiated in GermanyGlobal clinical trials of batoclimab are ongoing in myasthenia gravis (MG), thyroid eye disease (TED), and chronic inflammatory demyelinating polyneuropathy (CIDP) NEW YORK, May 22, 2023 (GLOBE NEW
InvestorPlaceThe Quant Trading System Picking Stocks That Soar 300%
Editor’s note: “The Quant Trading System Picking Stocks That Soar 300%” was previously published in January 2023. It has since been updated to include the most relevant information available. The stock market got crushed in 2022. It was a nasty year for most investors. But what if I told you that amid 2022’s financial market turmoil, there was a quantitative trading system that was regularly picking stocks that were soaring 100%, 200%, and even 300%-plus in a matter of months? InvestorPlace - St
BenzingaImmunovant Could Potentially Be An M&A Target, Writes Analyst
Cantor Fitzgerald initiated coverage on Immunovant Inc (NASDAQ: IMVT) with an Overweight rating and a price target of $30. The company's pipeline includes batoclimab (IMVT-1401) and IMVT-1402, fully human, monoclonal antibodies targeting the neonatal fragment crystallizable receptor (FcRn). Batoclimab has demonstrated its potential to reduce immunoglobulin G (IgG) antibodies that cause inflammation, while IMVT-1402 has also demonstrated profound IgG antibody reduction in animal studies. Related:
- GlobeNewswire
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
A Phase 1 clinical trial of IMVT-1402 is on track to be initiated in early calendar year 2023A Phase 3 clinical trial of batoclimab in thyroid eye disease (TED) and a Phase 2b clinical trial in chronic inflammatory demyelinating polyneuropathy (CIDP) were initiated, as expectedPhase 3 clinical trial of batoclimab in myasthenia gravis (MG) is ongoing Cash balance of approximately $433 million as of December 31, 2022 NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a cl
- Simply Wall St.
We Think Immunovant (NASDAQ:IMVT) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Immunovant...
ZacksThe Zacks Analyst Blog Highlights Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant
Merck, Vertex Pharmaceuticals, Immunocore Holdings and Immunovant are part of the Zacks top Analyst Blog.
Zacks4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023
Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.
ZacksAre Medical Stocks Lagging Immunovant (IMVT) This Year?
Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.
Insider Monkey12 Best Small-Cap Healthcare Stocks To Buy Now
In this article, we discuss 12 best small-cap healthcare stocks to buy now. If you want to see more stocks in this selection, check out 5 Best Small-Cap Healthcare Stocks to Buy Now. Macroeconomic headwinds and recessionary concerns will not weaken healthcare deals next year after the market experienced resilient mergers and acquisitions in 2022. […]
- Zacks
Are Medical Stocks Lagging BioVie (BIVI) This Year?
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
ZacksReasons to Add Immunovant (IMVT) Stock to Your Portfolio Now
Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
ZacksImmunovant (IMVT) Rises More Than 150% in 3 Months: Here's How
Immunovant (IMVT) is making good progress with its lead pipeline candidate, batoclimab, which is being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.
ZacksIs BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.
ZacksImmunovant's (IMVT) Q2 Earnings In Line, Batoclimab in Focus
Immunovant's (IMVT) earnings meet estimates in the fiscal second quarter ending Sep 30, 2022. IMVT deepens focus on developing its lead candidate batoclimab.
- GlobeNewswire
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
NEW YORK, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th-15th, 2022. Guggenheim 4th Annual Immunology and Neurology Day fireside chat details: Date:Monday, November 14th, 2022
- GlobeNewswire
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
IMVT-1402, a next generation, subcutaneously administered, neonatal fragment crystallizable receptor (FcRn) inhibitor unveiledNew development programs for batoclimab in chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease announcedPhase 3 trials of batoclimab in myasthenia gravis (MG) and thyroid eye disease (TED) progressing Pro forma cash balance of $476 million expected to extend cash runway into second half of calendar year 2025 NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE
ZacksImmunovant (IMVT) Set to Develop Lead Candidate Batoclimab
Immunovant (IMVT) expects its lead pipeline candidate, batoclimab, being developed for treating several types of autoimmune diseases, to capture good market share, owing to its differentiated profile.
- Simply Wall St.
While institutions invested in Immunovant, Inc. (NASDAQ:IMVT) benefited from last week's 63% gain, public companies stood to gain the most
A look at the shareholders of Immunovant, Inc. ( NASDAQ:IMVT ) can tell us which group is most powerful. With 57...
Motley FoolWhy Immunovant Stock Is Skyrocketing This Week
Shares of Immunovant (NASDAQ: IMVT) were skyrocketing 75.1% higher this week as of 3:42 p.m. ET on Thursday, according to data provided by S&P Global Market Intelligence. Most of this big gain came after the company announced a public offering on Tuesday to sell 12.5 million shares. Immunovant is issuing 12.5 million new shares, representing roughly 10.7% of its outstanding shares.
GlobeNewswireImmunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Deep Track Capital, Frazier Life Sciences, TCGX, BVF Partners L.P., Commodore Capital,
BenzingaImmunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
On Wednesday, Immunovant Inc (NASDAQ: IMVT) announced a new anti-FcRn, IMVT-1402, at Roivant Sciences Ltd's (NASDAQ: ROIV) Investor Day. IMVT-1402 is a new anti-FcRn monoclonal antibody that matches batoclimab's IgG lowering without affecting albumin and LDL. HC Wainwright says the addition of IMVT-1402 broadens the anti-FcRn franchise. The analyst maintains a Buy rating with a price target of $16. Roivant is leveraging data and learnings from batoclimab studies to accelerate IMVT-1402's develop
- GlobeNewswire
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023. Previously announced programs for lead asset batoclimab continue at full speed. Two asset anti-FcRn franchise offers multiple potential development and commercial synergies, with composition of matter patent protection expected for IMVT-1402 through at lea
Insider MonkeyThese 10 Stocks are Getting Crushed on Monday
In this article, we will take a look at the 10 stocks getting crushed on Monday. If you want to see some more companies on the list, go directly to These 5 Stocks are Getting Crushed on Monday. U.S. stocks inched up before the opening bell today. However, the gains couldn’t continue for long. All […]